Cognitive impairment is a core symptom domain of schizophrenia. The effect of
antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully …

Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia
because of their high clinical efficacy. However, SGA treatment is associated with severe …

Dopamine (DA) and DA receptors (DR) have been extensively studied in the central nervous
system (CNS), but their role in the periphery is still poorly understood. Here we summarize …

Background A relationship between non-neurological autoimmune (NNAI) disorders and
psychosis has been widely reported but not yet subjected to meta-analysis. We conducted …

Background Type 2 diabetes mellitus (T2DM) is linked with several neurodegenerative and
psychiatric disorders, either as a comorbid condition or as a risk factor. We aimed to expand …

The mortality rate of patients with schizophrenia is high, and life expectancy is shorter by 10
to 20 years. Metabolic abnormalities including type 2 diabetes mellitus (T2DM) are among …

Hypothalamic detection of elevated circulating glucose triggers suppression of endogenous
glucose production (EGP) to maintain glucose homeostasis. Antipsychotics alleviate …

Introduction To assess the risk of occurrence and potential determinants of metabolic
disorders in adult patients treated with second-generation antipsychotics (SGAs) under real …

Schizophrenia (SCZ) is a psychiatric disorder characterized by a wide range of positive,
negative and cognitive symptoms, along with an increased risk of metabolic syndrome and …

The epidemiologic link between schizophrenia (SCZ) and type 2 diabetes (T2D) remains
poorly understood. Here, we investigate the presence and extent of a shared genetic …